PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES
- PMID: 19871511
- PMCID: PMC2135567
PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES
Abstract
1. Immunization of man with 0.03 to 0.06 mg. of each of the capsular polysaccharides of pneumococcus types I, II, V, and VII, given in a single subcutaneous injection, has been shown to be effective in preventing pneumonia caused by these types but not that due to heterologous types. 2. Immunity appears within a period of 2 weeks following injection of the polysaccharides. Its duration was not determined, although 6 months can be set as a minimum. 3. Immunization of alternate subjects in the population reduced greatly the incidence of pneumonia in the non-immunized. 4. The carrier rate for pneumococcus types I, II, V, and VII was lowered significantly in the immunized group as compared with the controls. It is suggested that an over-all reduction in the incidence of carriers was responsible for the lowered rates for pneumococcal pneumonia in the non-immunized group.
Similar articles
-
Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides.J Exp Med. 1945;82:445-65. J Exp Med. 1945. PMID: 21006188 No abstract available.
-
Pneumococcal polysaccharide immunization of children with sickle cell disease. II. Serologic response and pneumococcal disease following immunization.Am J Pediatr Hematol Oncol. 1982 Spring;4(1):25-35. Am J Pediatr Hematol Oncol. 1982. PMID: 7091574
-
Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines.J Infect Dis. 1977 Aug;136 Suppl:S38-42. doi: 10.1093/infdis/136.supplement.s38. J Infect Dis. 1977. PMID: 19543
-
Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.Rev Infect Dis. 1981 Mar-Apr;3 Suppl:S1-17. doi: 10.1093/clinids/3.supplement_1.s1. Rev Infect Dis. 1981. PMID: 7025155 Review.
-
Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species.Int J Antimicrob Agents. 2008 Sep;32(3):199-206. doi: 10.1016/j.ijantimicag.2008.01.021. Epub 2008 Apr 18. Int J Antimicrob Agents. 2008. PMID: 18378430 Review.
Cited by
-
Fred Neufeld and pneumococcal serotypes: foundations for the discovery of the transforming principle.Cell Mol Life Sci. 2013 Jul;70(13):2225-36. doi: 10.1007/s00018-013-1351-z. Epub 2013 May 21. Cell Mol Life Sci. 2013. PMID: 23689587 Free PMC article.
-
Pneumococcal antibodies (IgG, IgM) in patients with chronic obstructive lung disease 3 years after pneumococcal vaccination.Med Microbiol Immunol. 1985;174(1):51-8. doi: 10.1007/BF02123671. Med Microbiol Immunol. 1985. PMID: 4000066
-
Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae.Infect Immun. 2001 Sep;69(9):5456-63. doi: 10.1128/IAI.69.9.5456-5463.2001. Infect Immun. 2001. PMID: 11500417 Free PMC article.
-
Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials.BMC Fam Pract. 2000;1:1. doi: 10.1186/1471-2296-1-1. Epub 2000 Oct 4. BMC Fam Pract. 2000. PMID: 11038265 Free PMC article.
-
Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection.Infect Immun. 2002 Mar;70(3):1547-57. doi: 10.1128/IAI.70.3.1547-1557.2002. Infect Immun. 2002. PMID: 11854243 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources